Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
AssigneeXigen Inflammation Ltd.
InventorChristophe Bonny
Life of this patent
Estimating the term…
Abstract
Protein kinase inhibitors and more specifically inhibitors of the protein kinase c-Jun amino terminal kinase are herein described. Additionally, JNK inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with JNK signaling are herein provided.
Claims21
JNK inhibitor sequence comprising less than 150 amino adds in length, wherein the inhibitor sequence comprises or consists of at least one amino acid sequence according to SEQ ID NOs:
- 1, 2, 3 or 4, or a fragment, derivative or variant thereof.
A chimeric peptide comprising at least one first domain and at least one second domain linked by a covalent bond, the first domain comprising a trafficking sequence, and the second domain comprising a JNK inhibitor sequence.
-23. (canceled)
Dependencies are inferred from the claim text.